Finding Description
Based on observations, staff interviews, record review, and policy review, the facility failed to ensure six of 47 sampled residents (R) (R#68, R#18, R#27, R#53, R#84, and R#34) were monitored for specific behaviors.
Findings include:
Review of facility policy titled, Assessment of Psychoactive Medication, undated, revealed, Patients who receive antipsychotic, sedative, hypnotic, antidepressant, or any medications prescribed to modify behavior are evaluated to determine the effectiveness of the medication . Based on a comprehensive assessment of a resident, the facility must ensure that . the facility must evaluate the effectiveness of the medications . After initiated or increasing the dose of a psychotropic medication, the behavioral symptoms much be reevaluated periodically to determine the potential for reducing or discontinuing the dose.
1. Review of R#68's Face Sheet located in the electronic medical record (EMR) under the Basic Information tab, revealed an admission date of 4/30/22, with medical diagnoses that included schizoaffective disorder (severe mental illness of hallucinations (hearing, seeing, touching, smelling objects not present) and delusions (firmly held beliefs not based on reality), insomnia, unspecified psychosis (disconnection from reality), major depression, anxiety disorder, bipolar disorder (mental illness of periods of depression and elevated mood), auditory hallucinations.
Review of R#68's quarterly Minimum Data Set (MDS) located in the EMR under the MDS tab with an Assessment Reference Date (ARD) of 10/21/22, revealed a Brief Interview for Mental Status (BIMS) score of 13 out of 15, indicating R#68 was cognitively intact. The MDS revealed R#68 had physical behaviors directed toward others and required supervision for all activities of daily living (ADL).
Review of R#68's Care Plan, located in the EMR under the Care Plan tab with a problem onset date of 11/8/22, revealed R#68 Displayed physically/verbally aggressive behaviors when I feel that I am being attached either verbally or physically by other residents. Goal: I will not display any physically/verbally aggressive behaviors towards other residents. Approaches: Social Services to evaluate and visit with me, Activities staff to visit with me . Monitor and document my behavior .Identify causes for my behavior . Discuss my options . praise me for demonstrating desired behavior, talk with me in a calm voice.
Review of R#68's Medication Administration Record (MAR) located in the EMR under the Orders tab, dated November 2022, revealed Zyprexa [anti-psychotic] 5 mg [milligram] tablet, take 1 tablet by mouth at HS [bedtime], start date 10/20/22, for anxiety disorder, Behavior Monitoring for Psychotropic Drugs - Observe for mood swing, agitation, restlessness, tardive dyskinesia every shift, start date 11/12/22.
During an interview with Licensed Practical Nurse (LPN) 2 on 11/10/22 at 1:20 p.m., LPN2 stated if R#68 had behaviors, staff would review the care plan, look at interventions, and document the behaviors in the nurses' behavior notes. She stated anytime abnormal behavior with a resident is observed, the behavior should be documented in the behavior notes. LPN2 reviewed the notes and confirmed there were no specific behaviors documented from 5/1/22 through 11/10/22 and specific behaviors were not in the care plan.
2. During an observation of R#18, on 11/7/22 at 10:27 a.m., R#18 was smiling and kissing a baby doll.
During an observation of R#18, on 11/7/22 at 11:10 a.m., R#18 was sitting in her wheelchair outside of her room. She was crying and holding two baby dolls.
During an observation of R#18, on 11/8/22 at 1:35 p.m., R#18 was sitting up in bed, holding one baby doll and laughing.
During an observation of R#18, on 11/11/22 at 2:05 p.m., R#18 was sitting in her wheelchair in her room. She was crying and holding one baby doll.
During an observation of R#18, on 11/12/22 at 1:15 p.m., R#18 was sitting in her wheelchair in her room. She was crying and holding two baby dolls.
During an interview with Certified Nursing Assistant (CNA) 4, on 11/11/22 at 2:05 p.m., CNA4 stated if she observed a behavior, she would report the behavior to the nurse. She stated that crying was a behavior. She stated she had not received any special education related to working with R#18 or her specific behaviors.
Review of R#18's Face Sheet located in the EMR under the Basic Information tab, revealed an admission date of 1/18/21, with medical diagnoses that included major depression and psychotic disorder with delusions.
Review of R#18's quarterly MDS located in the EMR under the MDS tab with an ARD of 10/1/22, revealed a BIMS score of three out of 15, indicating R#18 was severely impaired cognitively. The MDS revealed no mood or behavior symptoms.
Review of R#18's Care Plan, located in the EMR under the Care Plan tab and reviewed 7/18/22, revealed R#18 did not have any behavior care plans.
Review of R#18's MAR located in the EMR under the Orders tab, dated November 2022, revealed Mirtazapine [antidepressant] 15 mg tablet by mouth at bedtime, start date 5/25/22, for major depressive disorder. Xanax [antianxiety] .5 mg tablet, take one tablet by mouth at bedtime, start date 11/3/22 for dementia. Further review of the November 2022 MAR revealed no identification and/or monitoring of target behaviors for the use of the antidepressant and antianxiety medications.
3. Review of R#27's Face Sheet, located in the EMR under the Basic Information tab, revealed an admission date of 7/18/22, with medical diagnoses that included bipolar disorder, major depression, schizophrenia, unspecified psychosis, and insomnia.
Review of R#27's quarterly MDS located in the EMR under the MDS tab with an ARD of 10/24/22, revealed a BIMS score of nine out of 15, indicating R#27 was moderately impaired cognitively. The MDS revealed no mood or behavior symptoms.
Review of R#27's Care Plan, located in the EMR under the Care Plan tab and reviewed 7/18/22, revealed R#27 did not have any behavior care plans.
Review of R#27's MAR located in the EMR under the Orders tab, dated November 2022, revealed Valproic Acid [Anticonvulsant] 250 mg/5ml [milliliters] soln [solution], give 750 mg per peg tube two times a day, start date 7/18/22 for Bipolar Disorder. Further review of the November 2022 MAR revealed no identification and/or monitoring of target behaviors for the use of Valproic Acid for bipolar disorder.
4. Review of R#53's Face Sheet, located in the EMR under the Basic Information tab, revealed an admission date of 8/9/22, with medical diagnoses that included generalized anxiety disorder, major depression, and insomnia.
Review of R#53's quarterly MDS located in the EMR under the MDS tab with an ARD of 10/2/22, revealed a BIMS score of 15 out of 15, indicating R#53 was cognitively intact. The MDS revealed no mood or behavior symptoms
Review of R#53's Care Plan, located in the EMR under the Care Plan tab and reviewed 7/23/22, revealed R#53 did not have any behavior care plans.
Review of R#53's MAR, located in the EMR under the Orders tab and dated November 2022, revealed Alprazolam [Antianxiety] .5 mg tablet, give one tablet by mouth daily at HS scheduled, start date 8/9/22 for generalized anxiety disorder. Further review of the November 2022 MAR revealed no identification and/or monitoring of target behaviors for the use of the antianxiety medication.
5. Review of R#84's Face Sheet, located in the EMR under the Basic Information tab, revealed an admission date of 7/28/21, with medical diagnoses that included unspecified psychosis, major depression, restlessness, and agitation.
Review of R#84's quarterly MDS located in the EMR under the MDS tab with an ARD of 10/7/22, revealed a BIMS score of three out of 15, indicating R#84 was severely impaired cognitively. The MDS revealed no mood symptoms, but documented R#84 had delusions.
Review of R#84's Care Plan, located in the EMR under the Care Plan tab and reviewed 9/28/22, revealed R#84 did not have any behavior care plans or identification of what delusions R#84 exhibited, and staff were to monitor.
Review of R#84's MAR located in the EMR under the Orders tab and dated November 2022, revealed Divalproex SOD DR [Anticonvulsant] 250 mg tab[let] take one tablet by mouth twice a day at 9:00 a.m. and 1:00 p.m., start date 8/10/21 for unspecified psychosis. Divalproex SOD DR 500 mg tab take one tablet daily at 5:00 p.m., start date 8/10/21 for unspecified psychosis. Depakote [Anticonvulsant] DR 250 mg tablet give one tablet by mouth daily at 9:00 a.m. and 1:00 p.m., start date 8/5/21 for unspecified psychosis. Behavior monitoring for psychotropic drugs: Observe for s/s [signs/symptoms] of psychotic behavior (mood change, crying, anger, etc.). start date 11/12/22. Further review of the November 2022 MAR revealed no monitoring of signs and symptoms of psychotic behavior.
6. Review of R#34's Face Sheet, located in the EMR under the Basic Information tab, revealed an admission date of 6/9/22 with medical diagnoses that included muscle wasting and morbid obesity.
Review of R#34's quarterly MDS located in the EMR under the MDS tab with an ARD of 10/2/22, revealed a BIMS score of 15 out of 15, indicating R#34 was cognitively intact. The MDS revealed R#34 had no behaviors documented.
Review of R#34's Care Plan, located in the EMR under the Care Plan tab and reviewed 10/2/22, revealed R#34 did not have any behavior care plans.
Review of R#34's MAR located in the EMR under the Orders tab and dated November 2022, revealed Ativan [Antianxiety]) .5 mg tablet, give 1 by mouth daily at bedtime, start 11/7/22 for Anxiety Disorder. Celexa [Antidepressant] 20 mg tablet take one tablet by mouth daily, start date 10/21/22 for major depression. Mirtazapine [Antidepressant]) 15 mg tablet take one tablet by mouth at bedtime, start date 6/17/22 for major depression. Monitor for s/s of restlessness/agitation/aggression due to use of anti-anxiety (Ativan), start date 11/12/22. Further review of the November 2022 MAR revealed no monitoring of the target behaviors/signs/symptoms for the use of the antianxiety medications.
During an interview with the Assistant Director of Nursing (ADON) on 11/11/22 at 1:01 p.m., the ADON stated monitoring all residents' behaviors was very important and behaviors should be identified and written in the care plan. She stated that behaviors should also be documented on the MAR and monitored every shift. She stated that monitoring changes in mood, expression, and observations of irritation, anger or crying, were very important behaviors to monitor. The ADON confirmed behaviors were not documented on the MAR.
During an interview with LPN4, on 11/11/22 at 1:44 p.m., LPN4 stated if a resident had behaviors, she would notify the social worker or the Administrator. She stated there was no written communication they would just communicate as the social worker walked by the nurses' station. She stated nurses should document but do not always do that.
During an interview with the Administrator on 11/11/22 at 12:00 p.m., the Administrator stated that she was sure the social work had not documented any information about any psychotropic or behavior meetings.